Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Liminatus Pharma ( (LIMN) ) is now available.
On January 15, 2026, Liminatus Pharma, Inc. received a notice from the Nasdaq Listing Qualifications Department that its shares were no longer in compliance with Nasdaq’s minimum $1 bid price requirement after trading below that threshold for 30 consecutive business days, though its stock will continue to trade under the ticker “LIMN” for now. The company has until July 14, 2026, a 180-day compliance window, to restore its bid price—potentially including a reverse stock split completed at least 10 business days before the deadline—or seek additional time, highlighting a period of uncertainty for shareholders as Liminatus works to regain compliance with Nasdaq listing rules.
More about Liminatus Pharma
Average Trading Volume: 249,161
Technical Sentiment Signal: Sell
Current Market Cap: $20.92M
For detailed information about LIMN stock, go to TipRanks’ Stock Analysis page.